Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Elizabeth I BuchbinderJanice P DutcherGregory A DanielsBrendan D CurtiSapna P PatelShernan G HoltanGerald P MiletelloMayer N FishmanRene GonzalezJoseph I ClarkJohn M RichartChristopher D LaoScott S TykodiAnn W SilkDavid F McDermottPublished in: Journal for immunotherapy of cancer (2019)
In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy.